Literature DB >> 8365814

Disseminated intravascular coagulation associated with disseminated cryptococcosis in a patient with acquired immunodeficiency syndrome.

G Fera1, N Semeraro, V De Mitrio, O Schiraldi.   

Abstract

Disseminated intravascular coagulation (DIC) is uncommon in acquired immunodeficiency syndrome (AIDS), despite the high incidence of infectious diseases. We describe an HIV-infected patient presenting with disseminated cryptococcosis, who had clear-cut laboratory evidence of progressively worsening DIC (thrombocytopenia, prolonged prothrombin time and partial thromboplastin time, hypofibrinogenemia, increased fibrin(ogen) degradation products and D-Dimer, reduced antithrombin III), although the clinical signs of the disease were rather scarce. The patient died despite intense treatment, which included heparin and fresh frozen plasma, and DIC was confirmed histologically. It is suggested that, in a patient with AIDS presenting with an opportunistic infection, laboratory signs of DIC should be carefully checked to early recognize this complication and promptly initiate the required therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8365814     DOI: 10.1007/bf01710541

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Ischaemic myelopathy secondary to disseminated intravascular coagulation in AIDS.

Authors:  G Fenelon; F Gray; F Scaravilli; F Mahieux; R Gherardi; P Chemouilli; A Guillard
Journal:  J Neurol       Date:  1991-02       Impact factor: 4.849

2.  Disseminated cryptococcosis diagnosed on peripheral blood smear in a patient with acquired immunodeficiency syndrome.

Authors:  J D Yao; C F Arkin; J P Doweiko; S M Hammer
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

Review 3.  Disseminated intravascular coagulation and related syndromes: a clinical review.

Authors:  R L Bick
Journal:  Semin Thromb Hemost       Date:  1988-10       Impact factor: 4.180

4.  Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome.

Authors:  S L Chuck; M A Sande
Journal:  N Engl J Med       Date:  1989-09-21       Impact factor: 91.245

Review 5.  Current concepts in cryptococcosis.

Authors:  T F Patterson; V T Andriole
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

6.  Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.

Authors:  A M Sugar; C Saunders
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

7.  Role of leukocytes in the activation of intravascular coagulation in patients with septicemia.

Authors:  K Okajima; W P Yang; H Okabe; M Inoue; K Takatsuki
Journal:  Am J Hematol       Date:  1991-04       Impact factor: 10.047

8.  A selective defect in tissue factor mRNA expression in monocytes from AIDS patients.

Authors:  J L Lathey; J M Agosti; J A Nelson; L Corey; S A Gregory; J H Morrissey; T S Edgington; M B Oldstone
Journal:  Clin Immunol Immunopathol       Date:  1990-01

9.  [Neuropathologic study of 135 adult cases of acquired immunodeficiency syndrome (AIDS)].

Authors:  F Gray; C Geny; F Lionnet; E Dournon; G Fenelon; R Gherardi; J Poirier
Journal:  Ann Pathol       Date:  1991       Impact factor: 0.407

Review 10.  The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis.

Authors:  S M Levitz
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec
View more
  2 in total

1.  Disseminated Mycobacterium avium-Intracellulare Complex Infection Presenting With Disseminated Intravascular Coagulation in an AIDS Patient.

Authors:  Folusakin Ayoade; James Cotelingam; Andrew Stevenson Joel Chandranesan
Journal:  J Investig Med High Impact Case Rep       Date:  2017-11-14

2.  Pathogenic factors associated with development of disseminated intravascular coagulopathy (DIC) in a tertiary academic hospital in South Africa.

Authors:  Elizabeth S Mayne; Anthony L H Mayne; Susan J Louw
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.